BSX vs REGN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BSX presents a classic divergence between deteriorating technicals and strong fundamental growth. While the Piotroski F-Score of 4/9 indicates stable but not exceptional financial health, the company exhibits robust revenue (15.9%) and earnings (18.5%) growth. The stock is currently trading near its growth-based intrinsic value ($55.75) and significantly below analyst targets ($96.66), with a highly attractive PEG ratio of 0.66 suggesting undervaluation relative to growth. Despite a severe 6-month price decline, the consistent track record of earnings beats and a low Forward P/E (15.26) support a bullish long-term outlook.
REGN shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics. Price trades at a 165.9% premium to fair value estimate ($290.57), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
BSX vs REGN: Head-to-Head Comparison
This page compares Boston Scientific Corporation (BSX) and Regeneron Pharmaceuticals, Inc. (REGN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.